Last $17.44 USD
Change Today -0.45 / -2.52%
Volume 916.8K
RGLS On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 11/25/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Kleanthis G. Xanthopoulos Ph.D.

Chief Executive Officer, President, Principal Financial & Accounting Officer and Director, Regulus Therapeutics Inc.
AgeTotal Calculated CompensationThis person is connected to 137 board members in 6 different organizations across 11 different industries.

See Board Relationships
56$2,641,363
As of Fiscal Year 2013

Background*

Dr. Kleanthis G. Xanthopoulos, Ph.D., has been the Chief Executive Officer and President of Regulus Therapeutics Inc., since January 2009 and also has been its Principal Financial & Accounting Officer since June 21, 2013. Dr. Xanthopoulos serves as the Managing Director of Life Science Investments at Novera Optics, Inc. He serves as Senior Vice President at Isis Pharmaceuticals, Inc. He serves as a Member of the Executive Board at BIOCOM, Inc. He founded Sente, Inc. ...

Read Full Background

Corporate Headquarters*

3545 John Hopkins Court
San Diego, California 92121

United States

Phone: 858-202-6300
Fax: --

Board Members Memberships*

Director
Former Director
Director
Founder and Director
2000-2011
Former Director and Member of Audit Committee
2009-Present
Chief Executive Officer, President, Principal Financial & Accounting Officer and Director
2011-Present
Chairman of the Board
2013-Present
Director, Member of Compensation Committee and Member of Nominating & Corporate Governance Committee
2013-2014
Former Director

Education*

MS
Stockholms universitet
PhD
Stockholms universitet
BS
University of Thessaloniki

Other Affiliations*

Annual Compensation*

Salary$600,000
Total Annual Compensation$600,000

Stock Options*

All Other Compensation$4,540
Exercisable Options916,999
Unexercisable Options458,284
Total Number of Options1,595,283

Total Compensation*

Total Annual Cash Compensation$964,540
Total Short Term Compensation$600,000
Other Long Term Compensation$4,540
Total Calculated Compensation$2,641,363
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGLS:US $17.44 USD -0.45

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ali Mortazavi Chief Executive and Director
Silence Therapeutics plc
70.0K GBP
Peter French B.Sc, M.Sc, Ph.D., MBAManaging Director, Chief Executive Officer and Director
Benitec Biopharma Limited
A$450.0K
Hans G. C. P. Schikan Chief Executive Officer and Member of Management Board
Prosensa Holding N.V.
--
Mark W. Schwartz Ph.D.Chief Executive Officer and President
Galena Biopharma, Inc.
$490.0K
Mark J. Murray Ph.D.Chief Executive Officer, President and Director
Tekmira Pharmaceuticals Corporation
$377.5K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGULUS THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.